Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.

Advanced Cardiovascular Systems, Inc. develops and manufactures cardiovascular medical products. It operates as a subsidiary of Abbott Laboratories. Its medical devices help patients with heart diseases in returning to active and productive lives and physicians for improving patient management and clinical outcomes. Advanced Cardiovascular Systems, Inc. is based in Santa Clara, California. it is currently known as Abbott Cardiovascular Systems.

AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany. The company is dedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.

Cardiac Pacemakers, Inc.(CPI), doing business as Guidant Cardiac Rhythm Management, manufactured implantable cardiac rhythm management devices, such as pacemakers and defibrillators. It also sold insulin pumps controlled by microprocessors and various equipments to regulate heart rhythm. In addition, Cardiac Pacemakers, Inc. developed therapies for the treatment of irregular heartbeats. The company was founded in 1971 and is based in St. Paul, Minnesota. Cardiac Pacemakers, Inc. operates as a subsidiary of Boston Scientific Corporation.

TAP Pharmaceutical Products was formed in 1977 as a joint venture between the two global pharmaceutical companies, Abbott Laboratories and Takeda Pharmaceutical Co. The company markets Prevacid and Lupron Depot, both leaders in their classes. Joint venture came to an end in March 2008 and Takeda took over the TAP. Lupron Depot is indicated for the palliative treatment of advanced prostate cancer, for management of endometriosis, in combination with iron for the preoperative treatment of anemia caused by uterine fibroids, and for the treatment of children with central precocious puberty.

Nephrogen is a biotech company in New York City developing curative gene therapies for kidney diseases. Our initial focus is on polycystic kidney disease (PKD), which affects 600,000 Americans and has no effective treatment or cure.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Develops and manufactures biologic products

Biosense Webster, Inc. is the global leader in the science of diagnosing and treating heart rhythm disorders. The company partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide. Biosense Webster is part of the Johnson & Johnson Family of Companies. More information can be found at www.biosensewebster.com.

Beijing Qingmei Lianchuang Stem Cell Technology Co., Ltd., established on 2009-03-26, Business scope includes technology development,technology transfer,technical consulting,Technical Services,Technology Promotion;Medical Research and Experimental Development;business management;Conference Services;public relations service;sale gift.(Market entities independently choose business projects in accordance with the law,Carry out business activities;and items that are legally subject to approval,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Chengdu Shilian Kangjian Biotechnology Co., Ltd., established on 2018-08-16, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Human stem cell technology development and application;Development of Human Gene Diagnosis and Therapy Technology;R&D and application of cell technology;Medical Research and Experimental Development;Health Consulting Services(Does not include medical services);Sales of Class I Medical Devices;Sales of Class II Medical Devices;Pharmaceutical special equipment sales;Research and development of bio-based materials technology;Sales of bio-based materials;software development;Information system integration service;Data processing and storage support services;Information Consulting Service(Not including licensing information consulting services);Engineering and Technology Research and Experimental Development;Machinery sales;electronics sales;Daily necessities sales;Hardware retail;Cosmetics Retail;Business Management Consulting;Corporate Image Planning;marketing planning;Advertising Design,acting;advertising(non-broadcasting station,television station,Newspaper Publishing Unit)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Medical beauty service;medical service;Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).

Sonablate Corp. develops and manufactures high intensity focused ultrasound surgical ablation systems. Its products include Sonablate 450, a HIFU solution that determines the safety and efficacy of a minimally invasive prostate cancer treatment; Sonablate 500, a HIFU surgical ablation system for the treatment of localized prostate cancer that delivers ablative therapy with the possibility of reducing side effects; and Sonatherm, a laparoscopic HIFU surgical ablation system that uses a laparoscopic probe to deliver robotic ablative therapy to soft tissue with a customizable ablation zone. The company was founded by Stephen R. Puckett Sr. and George M. Suarez in 2004 and is headquartered in Charlotte, NC.

Shanghai Liwo Biotechnology Co., Ltd., established on 2011-08-23, Business scope includes technology development in the field of biotechnology,technical consulting,technology transfer,Technical Services,e-commerce(Not allowed to engage in value-added telecommunications,Financial services),Daily necessities,Sales of Class I Medical Devices,medical consultation(Do not engage in medical activities),Health Advisory(Do not engage in medical activities,psychological counseling),Health Management Consulting(Do not engage in medical activities,psychological counseling),Cultural and artistic exchange planning,Other Resident Services. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]